Spanish pharmaceutical company, Ferrer, have announced they have completed recruitment of 220 patients for the PROSPER Study, two months ahead of schedule. The study is a Phase 2 clinical trial a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in PSP.
The PROSPER study is a randomized, double-blind, placebo-controlled trial that has successfully recruited the planned number of 220 participants with PSP in just 14 months, achieving this milestone on 6 October, two months ahead of schedule. A total of 44 centers across the European Union, the United Kingdom, and the United States are taking part. The study design includes a six-week screening period, followed by 52 weeks’ treatment with either FNP-223 or placebo and a subsequent four-week follow-up period after the completion of treatment.
You can read more about the study here.
